Metropolis Healthcare Latest Share Price (METROPOLIS)
TODAY IN ONE LINE
METROPOLIS edged up 0.5% on light volume, in line with Nifty's -0.4% move, supported by recent strong earnings.
With a market cap of ₹11,745.36 Cr., it trades at a P/E of 58.01. Track live valuations, technical indicators, and peers comparison below. Check delivery conviction and recent filings to build your view.
How good is this company?
Overall performance across 5 key dimensions.
Metropolis Healthcare flags & news
Key strengths, potential risks, and recent updates.
Green Flags
- ●Earnings GrowthEPS (TTM) grew by a solid 73.0% YoY
- ●Quarterly OutperformanceLatest quarter Sales up 23.0% and Profit up 74.4%
- ●High Capital EfficiencyROCE of 17.8% indicating pricing power
- ●Healthy Operating MarginsOPM is structurally strong at 24.4%
- ●Virtually Debt-FreeVery low Debt-to-Equity of 0.15x
- ●Positive Free Cash FlowFCF has been positive for 3 consecutive years
- ●Zero Pledge RiskNo recent active promoter pledging found
Red Flags
- ●Expensive ValuationTrading at a high P/E ratio of 58.9x
- ●Rising Receivables vs SalesReceivables grew 16.2% outpacing sales growth of 10.2%
Latest Metropolis Healthcare News
What changed recently?
Recent events, corporate actions, and announcements.
Metropolis Healthcare Limited valuation: P/E, P/B and sector benchmarks.
Twelve years of multiples investors have paid for Metropolis Healthcare Limited, framed against the sector median so the premium or discount is obvious at a glance.
Metropolis Healthcare Limited trades at a P/E of 58.01× and P/B of 7.73×.
Market-priced ratios use the latest available quote; accounting metrics use the latest reported filing. Compare values with matched peers and the company's own history.
Valuation
Profitability
Growth
Financial Health
Metropolis Healthcare Limited technical analysis: indicators, pivots and CPR.
Latest RSI, MACD and moving-average signals plus the latest pivot and Central Pivot Range levels for Metropolis Healthcare Limited — derived from the latest tape, not yesterday's close.
Metropolis Healthcare Limited last traded at ₹566.25 with an intraday range of ₹563–₹567.7 — latest indicator, pivot and CPR signals below.
Pivot points
Standard pivot — most widely referenced.
Pivot levels · Classic
Last: ₹566.25| Level | Price (₹) | Distance | % Δ |
|---|---|---|---|
| R4 | 577.70 | +11.45 | +2.02% |
| R3 | 573.00 | +6.75 | +1.19% |
| R2 | 570.35 | +4.10 | +0.72% |
| R1 | 568.30 | +2.05 | +0.36% |
| PIVOT | 565.65 | -0.60 | -0.11% |
| CURRENT | 566.25 | — | — |
| S1 | 563.60 | -2.65 | -0.47% |
| S2 | 560.95 | -5.30 | -0.94% |
| S3 | 558.90 | -7.35 | -1.30% |
| S4 | 554.20 | -12.05 | -2.13% |
METROPOLIS is trading Above CPR, indicating Bullishness
CPR is Narrower, suggesting likely for trending moves
Day's range: ₹563–₹567.7
Trading Inside opening range
Metropolis Healthcare Limited financials: P&L, balance sheet, cash flow, ratios.
Reported annual and quarterly results for Metropolis Healthcare Limited — consolidated or standalone — with margins, YoY growth and key ratios inline.
Metropolis Healthcare Limited reports its full P&L, balance sheet, cash flow and ratios on this page — current market capitalisation of ₹11,745.36 Cr. and reported EPS of ₹9.17.
| Metric | Mar 2025 | Mar 2026 |
|---|---|---|
| Revenue from Operations | 1,331 | 1,646 ▲ 23.6% |
| Sales Growth YoY %Derived | 10.23% | 23.64% |
| Other Income | 15 | 26 ▲ 69.3% |
| Total Income | 1,346 | 1,671 ▲ 24.1% |
| 269 | 325 ▲ 20.8% | |
| Gross ProfitDerived | 1,063 | 1,321 ▲ 24.4% |
| Gross Margin %Derived | 79.82% | 80.28% |
| 760 | 920 ▲ 21.2% | |
| EBITDA (Operating Profit)Derived | 303 | 401 ▲ 32.3% |
| OPM %Derived | 22.76% | 24.36% |
| 127 | 149 ▲ 17.3% | |
| Profit Before Tax (PBT) | 191 | 259 ▲ 35.8% |
| 45 | 68 ▲ 50.0% | |
| Effective Tax %Derived | 23.76% | 26.23% |
| Total Profit for Period | 146 | 191 ▲ 31.4% |
| Less: Non-controlling Interests | 1 | 1 ▲ 113.5% |
| Net Profit (Owner's PAT)Derived | 145 | 190 ▲ 31.1% |
| Net Profit Margin %Derived | 10.89% | 11.55% |
| PAT Growth YoY %Derived | 13.42% | 31.08% |
| Earnings Per Share (EPS ₹) | 7.00 | 9.17 ▲ 31.0% |
| Diluted Shares Outstanding (Cr) | 21 | 21 ▲ 0.1% |
| Share of Profit from Associates/JVs | — | — |
| Other Comprehensive Income (Net of Tax) | -0 | 5 ▲ 1642.2% |
| Total Expenses (incl. D&A & Interest) | 1,155 | 1,412 ▲ 22.2% |
| Material Cost % of RevenueDerived | 20.18% | 19.72% |
| Employee Cost % of RevenueDerived | 23.57% | 22.93% |
| Other Cost % of RevenueDerived | 33.49% | 33.00% |
| Interest Coverage (x)Derived | 10.46x | 10.88x |
| Period | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Trend |
|---|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | 761 | 856 ▲ 12.5% | 998 ▲ 16.5% | 1,228 ▲ 23.1% | 1,148 ▼ 6.5% | 1,208 ▲ 5.2% | 1,331 ▲ 10.2% | 1,646 ▲ 23.6% | |
| Sales Growth YoY %Derived | — | 12.51% | 16.53% | 23.08% | -6.52% | 5.18% | 10.23% | 23.64% | |
| Other Income | 8 | 9 ▲ 4.3% | 12 ▲ 40.6% | 18 ▲ 46.3% | 15 ▼ 13.6% | 9 ▼ 40.1% | 15 ▲ 65.8% | 26 ▲ 69.3% | |
| Total Income | 769 | 865 ▲ 12.4% | 1,010 ▲ 16.8% | 1,246 ▲ 23.4% | 1,163 ▼ 6.6% | 1,217 ▲ 4.6% | 1,346 ▲ 10.6% | 1,671 ▲ 24.1% | |
174 | 204 ▲ 17.7% | 252 ▲ 23.5% | 276 ▲ 9.5% | 253 ▼ 8.2% | 243 ▼ 4.2% | 269 ▲ 10.8% | 325 ▲ 20.8% | ||
| Gross ProfitDerived | 588 | 652 ▲ 11.0% | 746 ▲ 14.3% | 952 ▲ 27.7% | 895 ▼ 6.0% | 965 ▲ 7.8% | 1,063 ▲ 10.1% | 1,321 ▲ 24.4% | |
| Gross Margin %Derived | 77.21% | 76.16% | 74.73% | 77.53% | 77.94% | 79.91% | 79.82% | 80.28% | |
387 | 419 ▲ 8.3% | 460 ▲ 9.6% | 610 ▲ 32.6% | 607 ▼ 0.5% | 683 ▲ 12.5% | 760 ▲ 11.3% | 920 ▲ 21.2% | ||
| EBITDA (Operating Profit)Derived | 200 | 233 ▲ 16.2% | 286 ▲ 22.8% | 343 ▲ 19.9% | 288 ▼ 15.9% | 283 ▼ 2.0% | 303 ▲ 7.2% | 401 ▲ 32.3% | |
| OPM %Derived | 26.32% | 27.19% | 28.66% | 27.91% | 25.11% | 23.40% | 22.76% | 24.36% | |
19 | 23 ▲ 20.4% | 54 ▲ 132.7% | 99 ▲ 84.0% | 116 ▲ 17.3% | 117 ▲ 0.9% | 127 ▲ 8.8% | 149 ▲ 17.3% | ||
| Profit Before Tax (PBT) | 187 | 169 ▼ 9.3% | 244 ▲ 44.4% | 293 ▲ 20.1% | 188 ▼ 36.1% | 175 ▼ 6.8% | 191 ▲ 9.3% | 259 ▲ 35.8% | |
63 | 41 ▼ 34.6% | 61 ▲ 48.1% | 79 ▲ 29.0% | 44 ▼ 43.9% | 46 ▲ 4.8% | 45 ▼ 1.9% | 68 ▲ 50.0% | ||
| Effective Tax %Derived | 33.74% | 24.33% | 24.96% | 26.82% | 23.52% | 26.47% | 23.76% | 26.23% | |
| Total Profit for Period | 124 | 128 ▲ 3.2% | 183 ▲ 43.7% | 215 ▲ 17.1% | 143 ▼ 33.2% | 128 ▼ 10.4% | 146 ▲ 13.3% | 191 ▲ 31.4% | |
| Less: Non-controlling Interests | 3 | 0 ▼ 93.5% | 0 ▲ 11.9% | 1 ▲ 98.7% | 1 ▲ 1.5% | 1 ▲ 25.0% | 1 ▼ 14.7% | 1 ▲ 113.5% | |
| Net Profit (Owner's PAT)Derived | 120 | 127 ▲ 6.0% | 183 ▲ 43.8% | 214 ▲ 17.0% | 143 ▼ 33.3% | 128 ▼ 10.5% | 145 ▲ 13.4% | 190 ▲ 31.1% | |
| Net Profit Margin %Derived | 15.78% | 14.87% | 18.35% | 17.44% | 12.44% | 10.58% | 10.89% | 11.55% | |
| PAT Growth YoY %Derived | — | 5.97% | 43.80% | 16.98% | -33.29% | -10.54% | 13.42% | 31.08% | |
| Earnings Per Share (EPS ₹) | 5.99 | 6.29 ▲ 5.0% | 8.95 ▲ 42.3% | 10.46 ▲ 16.9% | 6.98 ▼ 33.3% | 6.24 ▼ 10.6% | 7.00 ▲ 12.2% | 9.17 ▲ 31.0% | |
| Diluted Shares Outstanding (Cr) | 20 | 20 ▲ 0.9% | 20 ▲ 1.0% | 20 ▲ 0.1% | 20 ▲ 0.1% | 20 ▲ 0.0% | 21 ▲ 1.1% | 21 ▲ 0.1% | |
| Share of Profit from Associates/JVs | — | -1 | — ▲ 100.0% | — | — | — | — | — | |
| Other Comprehensive Income (Net of Tax) | 1 | -3 ▼ 315.5% | -1 ▲ 64.0% | -2 ▼ 114.5% | -0 ▲ 85.0% | -1 ▼ 136.3% | -0 ▲ 62.0% | 5 ▲ 1642.2% | |
| Total Expenses (incl. D&A & Interest) | 583 | 696 ▲ 19.4% | 766 ▲ 10.1% | 953 ▲ 24.4% | 976 ▲ 2.4% | 1,042 ▲ 6.8% | 1,155 ▲ 10.9% | 1,412 ▲ 22.2% | |
| Material Cost % of RevenueDerived | 22.79% | 23.84% | 25.27% | 22.47% | 22.06% | 20.09% | 20.18% | 19.72% | |
| Employee Cost % of RevenueDerived | 23.15% | 22.20% | 19.90% | 18.98% | 22.01% | 22.84% | 23.57% | 22.93% | |
| Other Cost % of RevenueDerived | 27.73% | 26.77% | 26.17% | 30.64% | 30.82% | 33.68% | 33.49% | 33.00% | |
| Interest Coverage (x)Derived | 339.48x | 23.20x | 30.85x | 14.16x | 7.43x | 8.35x | 10.46x | 10.88x |
Metropolis Healthcare segment analysis : revenue and profit mix.
Disclosed business segments at Metropolis Healthcare with their share of revenue and profit, switchable between consolidated and standalone reporting.
Metropolis Healthcare discloses revenue and profit across multiple business segments — toggle between consolidated and standalone views to see the mix.
Segment-wise Financial Analysis
The Bull, Bear, and Flip case for Metropolis Healthcare Limited.
Our AI distills the core fundamental drivers supporting Metropolis Healthcare Limited, the risks that threaten it, and the quantitative conditions that could weaken the thesis.
Metropolis Healthcare Limited's investment case rests on 10 positive markers and 10 flagged concerns drawn from the latest reported filings.
What you're getting.
Latest quarterly EPS grew 74.7% YoY, demonstrating robust earnings momentum.
TTM revenue growth of 23% YoY significantly outpaces diagnostic sector peers.
Operating margin of 16.23% TTM reflects efficient cost management and operations.
Low debt-to-equity ratio of 0.0015 ensures strong financial flexibility and stability.
Operating cash flow of ₹317.89 Cr underpins sustainable investment capacity.
Key Risks.
Trailing P/E of 58.88x signals significant overvaluation versus sector peers.
Dividend yield of 0.36% offers minimal income return for equity investors.
FII holdings eased from 23.90% to 19.16%, signals foreign investor caution.
Stock trading near 52-week high of ₹608.95 limits near-term upside potential.
ROE of 13.8% and ROCE of 17.8% lag peer leaders THYROCARE and LALPATHLAB.
Flip Conditions.
Valuation risk. a P/E above 75 would leave less room for earnings disappointment.
Reassess if quarterly profit growth turns negative for two consecutive quarters. The bull case relies on compounding earnings.
Watch interest coverage if debt-to-equity climbs above 1.00. Balance sheet risk re-prices growth multiples fast.
Return-quality risk. ROE below 9% would indicate weaker capital compounding.
Metropolis Healthcare Limited peer comparison — same-sector benchmarks.
Same-sector listed peers ranked on P/E, market cap, dividend yield and growth — Metropolis Healthcare Limited is highlighted for quick read-across.
Quick Compare
Peer Comparison
| Company Name |
|---|
Metropolis Healthcare Limited chart patterns: breakouts, tops and bottoms.
Auto-detected classical chart patterns for Metropolis Healthcare Limited — Double Top/Bottom, Head & Shoulders, Triple Bottom and more — with break levels, targets and quality scores across Intraday, Daily and Weekly timeframes.
Metropolis Healthcare Limited delivery volume — last 20 sessions of conviction.
Daily traded volume and delivery percentage for Metropolis Healthcare Limited over 20 sessions — the gap between intraday flipping and genuine accumulation.
Latest session delivery in Metropolis Healthcare Limited stood at 50.3% of traded volume, against a 20-day average of 55.0%.
Metropolis Healthcare announcements: results, concalls, ratings, M&A.
Filings Metropolis Healthcare sent to the exchanges, sequenced as they hit the tape — concall transcripts, results, credit ratings and presentations.
Metropolis Healthcare files concall transcripts, results, credit ratings and corporate-action notices on the NSE and BSE exchange portals — latest 161 documents below.
Sale or disposal
Metropolis Healthcare Limited has informed the Exchange about disclosure under Regulation 30 of SEBI Listing Regulations
Analysts/Institutional Investor Meet/Con. Call Updates
Metropolis Healthcare Limited has informed the Exchange about meeting with investors scheduled on August 27, 2026
Shareholders meeting
Metropolis Healthcare Limited has submitted the Exchange a copy Scrutinizer's Report of Annual General Meeting held on August 18, 2026
Shareholders meeting
Metropolis Healthcare Limited has informed the Exchange regarding Proceedings of the 26th Annual General Meeting held on August 18, 2026
Analysts/Institutional Investor Meet/Con. Call Updates
Metropolis Healthcare Limited has informed the Exchange about Transcript
Investor decks & rating reports.
Investor Presentation
Investor Presentation
Investor Presentation
Investor Presentation
Investor Presentation
Investor Presentation
Metropolis Healthcare dividend history, splits and bonus issues.
Every dividend, stock split and bonus issue Metropolis Healthcare has declared, sequenced by announce and record date.
Metropolis Healthcare corporate-action history below covers all declared dividends, stock splits and bonus issues recorded with NSE and BSE.
Metropolis Healthcare insider trading: promoter and management activity.
Promoter, director and designated-employee transactions in Metropolis Healthcare as reported to SEBI — buying and selling signals from the people who know the business best.
Metropolis Healthcare insider activity below tracks 4 reported promoter, director and designated-employee transactions under SEBI Regulation 7(2).
| Insider | Category | Txn Date | Action | Quantity | Value (₹) | Price |
|---|---|---|---|---|---|---|
| Sushil Shah Family Trust | Insider | 29 May 2025 | buy | +11.67 L | — | — |
| Sushil Kanubhai Shah | Insider | 29 May 2025 | sell | −11.67 L | — | — |
| Duru Shah Family Trust | Insider | 26 Mar 2025 | buy | +7.66 L | — | — |
| Dr. Duru Sushil Shah | Insider | 26 Mar 2025 | sell | −7.66 L | — | — |
About Metropolis Healthcare Limited: business, sector, key facts.
What Metropolis Healthcare Limited does, where it operates, the people running it, and the numbers that describe the entity behind the ticker.
Metropolis Healthcare Limited operates in the Healthcare Service Provider industry under the Healthcare sector, listed as NSE: METROPOLIS, BSE: 542650.
Metropolis Healthcare Limited is a leading provider of diagnostic services in India and internationally. Their core business revolves around offering a comprehensive range of clinical laboratory testing and profiling services to individuals and corporate clients. This includes a wide array of tests designed for various medical specialties and purposes.
The company's services cater to a broad spectrum of medical needs. They provide diagnostic services specializing in oncology (cancer), neurology (nervous system), gynecology (women's health), and nephrology (kidney disease). This specialized focus allows them to offer highly targeted and accurate testing for a variety of health conditions.
Beyond specialized testing, Metropolis also offers a comprehensive suite of health check-up packages. These packages are tailored to different demographic groups, including men, women, senior citizens, youth, and corporate employees. This approach allows for preventative health measures and early detection of potential health problems.
The diagnostic services provided by Metropolis play a crucial role in various stages of healthcare. Their tests are used for disease prediction, early detection through screening, confirming diagnoses, and monitoring the progression of existing conditions. This comprehensive approach contributes significantly to effective healthcare management.
In addition to their core diagnostic services, Metropolis also offers corporate wellness programs. These programs are designed to improve the health and well-being of employees within organizations. They also provide laboratory information system services and support clinical research initiatives, further expanding their reach within the healthcare ecosystem.
Related
Peers, sector trends, screeners and strategy playbooks contextual to this stock.
- Health X Platform (HEALTHX) Share PricePeer
- Krsnaa Diagnostics (KRSNAA) Share PricePeer
- Dr Lal Path Labs (LALPATHLAB) Share PricePeer
- Suraksha Diagnostic (SURAKSHA) Share PricePeer
- Thyrocare Technologies (THYROCARE) Share PricePeer
- Other overvalued NSE stocksScreener
- Top Gainers TodayScreener
- EMA Crossover ScreenerScreener
- Stock Quality ScorecardScreener
- Technical DashboardScreener
- Results CalendarScreener
- FII Buying ActivityScreener
- All Technical ScreenersScreener
- All Trading StrategiesStrategy
Questions investors ask about Metropolis Healthcare Limited (METROPOLIS).
Quick answers grounded in this page's data — price action, fundamentals, ratios and ownership.
01What is the current share price of Metropolis Healthcare Limited (METROPOLIS)?
The current share price of Metropolis Healthcare Limited (METROPOLIS) is ₹566.25. Today, the stock has gained by ₹2.90 (0.51%), trading in a range of ₹563.00 to ₹567.70. The stock opened at ₹566.95 with a trading volume of 49,811 shares.
02Is Metropolis Healthcare Limited stock a good investment for long-term?
Metropolis Healthcare Limited can be considered for long-term investment based on several factors. The company has a market capitalization of ₹11,745.36 Cr., P/E ratio of 58.01, ROE of 13.8%, and ROCE of 17.8%. The dividend yield stands at 0.36%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
03What is the 52-week high and low price of Metropolis Healthcare Limited stock?
The 52-week high price of Metropolis Healthcare Limited (METROPOLIS) is ₹2,263.00, while the 52-week low is ₹412.25. Currently trading at ₹566.25, the stock is 37.36% above its 52-week low and 74.98% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
04Should I buy Metropolis Healthcare Limited stock at the current price?
Whether to buy Metropolis Healthcare Limited stock at ₹566.25 depends on multiple factors. The stock is currently trading with a P/E ratio of 58.01 and P/B ratio of 7.73. Today's performance shows a gain of 0.51%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
05What is the dividend yield of Metropolis Healthcare Limited and when is the next dividend?
Metropolis Healthcare Limited offers a dividend yield of 0.36%, which means for every ₹100 invested at the current price of ₹566.25, you can expect to receive approximately ₹0.36 annually as dividends. The face value of the stock is ₹2.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
06What are the key financial ratios and metrics of Metropolis Healthcare Limited?
Metropolis Healthcare Limited's key financial metrics include: P/E Ratio: 58.01, P/B Ratio: 7.73, ROE: 13.8%, ROCE: 17.8%, Dividend Yield: 0.36%, EPS: ₹9.17, Book Value: ₹73.13, and Debt-to-Equity: 0.15. The company's market cap stands at ₹11,745.36 Cr.. These metrics help evaluate the company's valuation, profitability, and financial health.
07How is Metropolis Healthcare Limited stock performing today in the market?
Metropolis Healthcare Limited stock opened at ₹566.95 and is currently trading at ₹566.25, showing a gain of ₹2.90 (0.51%). The intraday high is ₹567.70 and low is ₹563.00. The trading volume stands at 49,811 shares, indicating moderate market participation today.
08What is the P/E ratio of Metropolis Healthcare Limited and what does it indicate?
Metropolis Healthcare Limited has a Price-to-Earnings (P/E) ratio of 58.01, which means investors are willing to pay 58.01 for every ₹1 of earnings. With an EPS of ₹9.17, this P/E ratio suggests the stock may be trading at a premium, possibly due to high growth expectations. Compare this with industry peers and historical P/E ratios for better context.
The data, ratios and commentary about Metropolis Healthcare Limited (METROPOLIS) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.